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Identification of the renat erythropoietin.producing cells using trans.
genic mice. Regulation of erythropoietin production by the kidneys is
central to the control of erythropoiesis. Uncertainty about the identity
of the renal cells involved has been a major obstacle to understanding
this mechanism. We have used sequence from the mouse erythropoietin
locus to direct expression of a marker gene, SV4O T antigen, to these
cells in transgenic mice. The transgenic constructs contained an oligo-
nucleotide marker (Epo-M) or SV4O sequence (Epo-TAg) in the 5'
untranslated region of the mouse erythropoietin gene, flanked on each
side by 9 and 7.5 kb of DNA from the mouse erythropoietin locus.
Anemia-inducible expression of Epo-M and Epo-TAg was observed in
the kidney. In one of thirteen lines, homologous integration of Epo-TAg
into the mouse erythropoietin locus occurred. In transgenic mice
bearing Epo-TAg at homologous and heterologous insertion sites, renal
expression was restricted to a population of cells in the interstitium of
the cortex and outer medulla. Immunohistochemical characterization
by light and electron microscopy shows that these are the fibroblast-like
type I interstitial cells.
Erythropoietin (Epo) is a glycoprotein hormone which stim-
ulates erythropoiesis when oxygen delivery is reduced by
anemia or hypoxemia [reviewed in 1, 2]. In most species the
liver is the major site of production in fetal life [3]. The kidney
is the dominant organ of production in adult life [4], and Epo
deficiency is the most important component of the anemia
which complicates chronic renal disease [5].
In liver, hepatocytes are one source of Epo, with a contribu-
tion from an unidentified population of non-parenchymal cells
[6, 7]. In keeping with this, oxygen-regulated Epo production is
observed in the hepatoma cell lines Hep3B and HepG2 [8]. By
contrast, in kidney, numerous unsuccessful attempts have been
made to identify and grow Epo-producing cells and there is no
equivalent Epo-producing tissue culture cell line. Direct immu-
nohistochemical localization of Epo synthesis has not proved
possible, most probably because of lack of significant storage at
this site. A further difficulty with this approach arises from the
function of Epo as a circulating hormone which may re-enter
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the kidney by glomerular filtration [reviewed in 2]. In situ
hybridization has shown that the cells which synthesize Epo
mRNA lie within the renal cortex and the majority of studies
have indicated that they lie within the renal interstitium [7,
9—12]. Further characterization has been difficult. Based on
location and numerical assessment, peritubular capillary endo-
thelial cells have been considered likely candidates. However,
one very recent report describes localization of ecto-5'-nucle-
otidase (5' NT, which is expressed on renal interstitial fibro-
blast-like cells) on the majority of the cells containing Epo
mRNA [13]. Nevertheless, uncertainty regarding the identity
and characteristics of the renal Epo-producing cells has been a
major obstacle to the understanding of renal Epo gene regula-
tion and how production is controlled in health and disease. We
have employed a different approach in order to address this
issue.
In transgenic mice, integration of a marker gene together with
appropriate cis-acting control sequence permits tissue-specific
expression of the marker gene. This may facilitate localization
of expression by visualization of the marker gene product, or
promotion of tumor formation and cellular transformation using
an oncogenic protein [14, 15].
In this report we describe the production and pattern of
transgene expression in mice bearing mouse Epo transgenes,
including one in which the transgene integration occurred in a
homologous fashion, modifying one copy of the native Epo
gene. In the first set of mice the transgene was marked by
insertion of Bgl II linkers in the 5' untranslated region (Epo-M).
In the second set of mice, coding sequence of the viral onco-
gene, simian virus 40 T antigen (SV 40 T Ag), was inserted at
this site (Epo-TAg; Fig. 1). In each case, Epo sequence,
consisting of 9 kb of 5' flanking sequence, the gene itself, and
3.5 kb of 3' flanking sequence, was otherwise unchanged, to
preserve as many putative control regions in their natural
positions as possible. Transgene expression was examined in a
range of organs, and was found to be inducible by anemia in the
kidney and liver, providing information about the location of
sequences responsible for the direction and regulation of Epo
gene expression. Renal expression of Epo-TAg was always
confined to a population of cells within the cortical and outer
medullary interstitium. Immunohistochemical studies using
light and electron microscopy were used to characterize these
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cells and indicate that they are the fibroblast-like cell popula-
tion, also known as the Type I interstitial cells [16].
Methods
DNA constructs
DNA was prepared from a bacteriophage clone isolated from
a BALB/c mouse genomic library (Clontech, Palo Alto, Cali-
fornia, USA). The 16.5 kb clone contained the mouse Epo gene
together with 9 kb of 5' flanking sequence and approximately
3.5 kb of 3' flanking sequence. This DNA was subcloned into
pBluescriptSKll (Stratagene, La Jolla, California, USA) fol-
lowing which nested pairs of unique restriction enzyme sites
were used in successive subcloning procedures to generate a
456 bp Eagl-BamHI fragment in which the Ball site lying in the
Epo 5' untranslated region 65 bp from the cap site was unique.
This site was used for insertion of (a) Bgl II linkers
CAGATCTG (Epo-M) or (b) a linkered fragment consisting of
nucleotides 5235 to 2533 from the SV4O viral genome and
containing the entire T Ag coding sequence and poly A addition
sites (Epo-TAg; Fig. IA). The 16.5 kb Epo sequence was then
reconstructed by successive religations into the recombinant
plasmids used in the original subcloning procedures. Plasmid
sequence was removed from these constructs by restriction
enzyme digestion. Following purification, DNA for microinjec-
tion was dialyzed against 10 mr't Tris HCI pH 7.5, 0.1 mM
EDTA.
Recovery and handling of oocytes
Female C57BL/lO x CBA mice were super-ovulated and
mated with CFLP males (Interfauna, Huntingdon, UK) to
provide zygotes for injection. Male pronuclei were pressure-
injected with DNA as described [17]. Injected zygotes were
cultured overnight and two-cell embryos were transferred to
oviducts of recipient females that had mated with vasectomized
males the previous night. Established lines were maintained by
breeding with CFLP, MF1 (Harlan Olac, Bicester, UK) or
littermates.
DNA analyses
DNA for transgene identification was prepared from tail
biopsies. Transgenic mice were identified using Southern hy-
bridization to detect the introduced Bgl II site or using the
polymerase chain reaction with a common 5' primer, and a 3'
primer which was specific for each construct (Epo-M or Epo-
TAg). For identification by Southern hybridization, a 4.4 kb Bgl
II restriction fragment was detected by hybridization to a
labeled 1.1 kb PstI fragment (Fig. 1A). In the Epo-M transgene,
this Bgl II restriction fragment was reduced to 3.6 kb, and in the
Epo-TAg transgene it was increased to 6.3 kb. Approximate
copy number was determined by densitometric scanning of
autoradiographs and comparison of signals from the transgene
and endogenous genes, or by serial dilution of the transgenic
DNA with normal mouse DNA. The positions of three other
probes used to characterize end fragments are shown in Figure
1A.
Measurement of hematocrit and induction of anemia
Hematocrits were measured on samples obtained from the
tail vein or by cardiac puncture. Mice were rendered acutely
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Fig. 1. Diagram of transgenic constructs,
DNA probes and riboprobes. A. The 16.5 kb
of cloned DNA is shown, with the Epo gene
and its 5 exons (untranslated sequence is
shown shaded, translated sequence is solid).
Bgl II (B) and XbaJ (X) restriction sites are
indicated. The polymorphic Bgl II restriction
site at the 3' end of the gene is shown in
brackets. A novel Bgl II site (boxed) was
inserted in Epo-M to mark the transgene and
its transcripts. DNA probes used for Southern
hybridisation are shown as solid bars above
the sequence, and labeled 1, 2, 3 and Pstl.l
(see text). In Epo-TAg a 2.7 kb BglI/BamHI
restriction fragment of SV4O DNA was
inserted as shown (hatched). B. Riboprobes.
For detection of Epo-M transcripts, an XbaI/
x Sac! fragment of Epo-M was used to generate
a riboprobe which crossed the transcription
start site. The protected fragment from
correctly initiated transcription (221 bp) is
shown as a solid bar. Endogenous Epo
transcripts lacking the Bgl II insert were
cleaved into two fragments (arrowhead) of 148
and 65 bp. For detection of Epo-TAg
transcripts, an XbaI/StuI fragment of Epo-
TAg was used to generate a riboprobe which
crossed the transcription start site and
included SV4O TAg sequence. The protected
fragment from correctly initiated transcription(120 bp) is shown as a solid bar. The
endogenous Epo mRNA was cleaved at the
arrowhead to give a single fragment (65 bp).
x
100 bp Stu
Epo-TAg
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Table 1. Antibodies to cytoplasmic/surface antigens used in double-labeling experiments
Antigen Antibody Dilution Labeling in interstium Ref.
F4180 Ag Rabbit a/s 1:1000 Macrophages 21
Ecto-5'-nucleotidase Rabbit a/s 1:1000 Cortical fibroblast-like cells 22
Human factor VIII rAg Rabbit a/s 1:200 Endothelium (large vessel) —
CD4S M1/9.3.4.HL2 neat Leukocytes 23
Class II MHC (Ia) B21-2 neat Leukocyte subset 24
Thy 1 YBM 29.2.1 TG6 neat Leukocyte subset 25
Fibroblast marker ER-TR7 1:25 Fibroblast-like cells, connective tissue 26
PECAM/CD31 MEC 13.3 neat Endothelium 27
The Thy 1 and Class II MHC epitopes were not preserved in perfusion-fixed sections, and for these antibodies acetone-fixed frozen sections were
used. ER-TR7 was from Biogenesis (Bournemouth, UK), Rabbit anti-human factor VIlI-related antigen was from DAKO A/S (Glostrup,
Denmark). The source of other antibodies is given in the Acknowledgements.
anemic by intraperitoneal injection of up to 60 mg/kg phenyl-
hydrazine 36, 24 and 12 hours prior to sacrifice.
RNA analysis
Organs were homogenized in 4 M guanidinium thiocyanate.
RNA was purified on a cesium chloride gradient and stored as
an ethanol precipitate at —70°C prior to analysis. RNAse
protection assays were performed using a modification of the
method of Melton et a! [18], as described previously [19]. For
most organs, 150 g RNA was analyzed, however, for lung,
heart and ovary the RNA yield was lower, and 50 g RNA was
analyzed. Hybridization was performed overnight at 55°C (Epo-
TAg) or 60°C (Epo-M). Digestion with RNAse A + T1 was at
25°C for 30 minutes. Quantitative analysis of selected samples
was performed by scintillation counting of bands excised from
the dried gels. Continuously labeled antisense riboprobes were
produced using SP6 polymerase. For Epo-M expression, the
template was an XbaI-SacI fragment from the Epo-M transgene
which protected 221 bp of Epo-M transcripts (Fig. 1 B). The 8 bp
mismatch with the endogenous gene yielded 148 bp and 65 bp
protected species from endogenous Epo mRNA. Epo-TAg
transcripts were assayed using an XbaI-StuI riboprobe which
protected 120 bp of Epo-TAg and 65 bp of endogenous Epo
mRNA (Fig. 1B).
Immunohistochemistry
Kidneys were either frozen in liquid nitrogen or fixed by
perfusion in situ with PLP (2% paraformaldehyde-0.075 M
L-lysine monohydrochloride-0.0i M sodium periodate in 0.1 M
phosphate buffer) for 15 minutes at 110 mm Hg. Following
perfusion, kidneys were excised, the capsule removed, and
portions were processed separately for light and electron mi-
croscopy. For light microscopy, fixed material was either
embedded in paraffin, or frozen in liquid nitrogen following
equilibration in 30% sucrose (wt/vol). Immunohistochemistry
for SV4O T Ag alone was performed on 4 m paraffin sections
and double labeling was performed on 5 pm cryostat sections.
Detection of SV4O T Ag in paraffin sections following dewax-
ing in xylene required microwave resuscitation (in 0.01 M
sodium citrate, 750 W, 10 mm). The sections were then incu-
bated with a polyclonal rabbit antiserum or normal rabbit serum
(as a control) at 1:1000 dilution for 45 minutes, followed by
horseradish peroxidase (HRP)-conjugated swine anti-rabbit im-
munoglobulin. The substrate used was nickel-enhanced 3'3'di-
aminobenzidine (DAB). Sections were then either mounted
without counterstaining, or counterstained with periodic acid-
Schiff (PAS).
For double staining a biotin-conjugated monoclonal antibody
(mAb) to SV4O T Ag, pAb 419 [20] was first applied at a dilution
of 5 g/ml after blocking endogenous biotin. Endogenous
peroxidase was then blocked in 4 parts methanol/i part 3%
H202 for five minutes. Avidin-conjugated HRP (DAKO A/S,
Glostrup, Denmark) was applied (diluted 1:50), followed by
nickel-enhanced DAB. The sections were then labeled for
surface antigens using the rabbit polyclonal antisera or rat
mAbs as shown in Table 1. Prior to polyclonal antisera, normal
swine serum was applied at a 1:50 dilution for 10 minutes.
Rabbit polyclonal antibodies were detected with alkaline phos-
phatase-conjugated swine anti-rabbit immunoglobulin diluted
1:25 (DAKO AIS, Glostrup, Denmark). Rat monoclonal anti-
bodies were detected with alkaline phosphatase-conjugated
sheep anti-rat immunoglobulin Fab fragments diluted 1:500
(Boehringer Mannheim, Mannheim, Germany). Fast Red was
used as substrate for alkaline phosphatase. In all double-
staining experiments, two adjacent sections on the same slides
were stained as controls as follows: (i) with the substitution of
buffer alone for the biotinylated mAb to 5V40 T Ag, (ii) with
appropriate substitution for second antibodies (normal rabbit
serum for rabbit polyclonal antibodies, buffer for mAbs). Be-
tween each step in the staining procedures, the sections were
washed in Tris buffered saline. Following staining, sections
were counterstained lightly with hematoxylin, and photo-
graphed.
For electron microscopy, 1 mm wide radial strips were cut
from the kidney to include cortex and medulla. Samples were
rapidly dehydrated through cold ethanol, which was then
replaced by a 1:1 mixture of ethanol:LR White resin (London
Resin Co., Basingstoke, UK) for one hour, prior to overnight
impregnation in pure resin at —20°C. The samples were then
embedded in LR White and the blocks polymerized overnight at
70°C. One micrometer sections were cut and stained with Azure
A for light microscopy. Selected areas were then sectioned with
a diamond knife and placed on nickel grids for immunostaining.
A three-stage staining protocol was found to be optimal; non-
specific staining was blocked with 1% BSA and 1% Tween in
the staining solutions throughout. Grids were first floated on 25
d drops of rabbit polyclonal antisera (diluted 1:1000) to SV4O T
Ag, 5' NT or Toxoplasma gondii (negative control) for two
hours. This was followed by goat anti-rabbit immunoglobulins
(Sigma, Poole, UK) diluted 1:50 for one hour and finally rabbit
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Fig. 2. Evidence demonstrating homologous integration of the transgene in the 134.3 LC line. A. Restriction sites outside the injected DNA. The
diagram shows the 16,5 kb cloned region used in the transgenic construct (open box) which includes the Epo gene (solid box). The region of the
endogenous mouse gene flanking the transgenic DNA construct is shown as an open line. The following restriction sites are shown; Hindu! (H),
BamHI (B), KpnI (K), Eag! (B), Sal! (S), EcoRV (R), Xho! (X). The SV4O sequence (hatched) was shown to have inserted in the Epo gene using
these enzymes and the probes 2 and 3. With each enzyme digest shown in the table, restriction fragments of the appropriate lengths (kb) were
observed. In non-transgenic mice only those attributable to the endogenous gene were observed. B. Southern blot of mouse DNA digested with
Bgl II and probed with Probe Pstl .1 (see Fig. IA). The transgene is demonstrated to be inherited in an allelic fashion with the Epo gene in the 134.3
LC line. MF1 and CFLP mice give a single restriction fragment of length 4.4 kb (A). Nan mice are polymorphic for one of the Bgl II sites and give
two restriction fragments of 4.4 and 4.7kb (A and B). The transgene gives an additional fragment of 6.3kb (T). The marker lane (A) contains phage
lambda cut with Hindill. When a Nan mouse (genotype AB, lane 1) is mated with a 134.3 LC heterozygote (genotype AT, lane 2) offspring of
genotype BT, AT, AA and AB are observed (19 lanes labeled offspring), demonstrating that A is allelic with T. The genotype ABT was not
observed in any offspring of 134.3 LC heterozygotes mated with Nan. This blot shows all surviving offspring of four litters whose parents were
of genotype AB and AT.
anti-goat immunoglobulins conjugated to 10 nm colloidal gold
(Bio Cell Ltd., Cardiff, UK) for 30 minutes. The grids were then
stained with 2% uranyl acetate for six minutes prior to exami-
nation with a Jeol lOOCx electron microscope (Jeol, Tokyo,
Japan).
Results
Identjfication and characterization of transgenic lines
Four transgenic animals were identified among 74 F0 mice
born following injection with Epo-M. One of these four
founders (37.6) gave rise to two different types of transgenic F1
offspring, 37.6 LC (low copy) and 37.6 HC (high copy). Line
37.6 LC contained a single copy of Epo-M with approximately
7.2 kb of 5' sequence deleted, whereas 37.6 HC contained a
multi-copy array. Thus a total of five different Epo-M lines was
obtained.
Of 142 F0 mice born following injection with Epo-TAg, six
were transgenic. One of these (134.3) gave rise to a single
transgenic offspring (191.10) among 54 live born pups from five
litters. This offspring then gave rise to two types of transgenic
offspring, one bearing a multicopy transgene (134.3 HC) and the
other a single copy homologous recombination which replaced
one copy of the endogenous Epo gene (134.3 LC). One other
Epo-TAg founder (188.1) gave rise to two different types of
offspring (l88.1LC and 188. 1HC). Thus, in total, eight Epo-TAg
lines were obtained. Proof of homologous recombination of the
transgene in line 134.3 LC was obtained as follows:
(i) The 4.4 kb Bgl II fragment containing the endogenous Epo
gene was reduced in intensity on Southern hybridization of
DNA from mice heterozygous for the transgene.
(ii) Southern hybridization of the transgene was exactly as
predicted for a homologous insertion. No transgene-spe-
cific end fragments could be detected in restriction enzyme
digests with Bgl II, EcoRI and Hindu! using probes lying
outside the most peripheral sites in the transgene for those
enzymes. More importantly, six enzymes were identified
which enabled positive identification of a transgene-spe-
cific restriction fragment which was in each case exactly
the length predicted for homologous insertion (Fig. 2A).
(iii) In offspring of matings between 134.3 LC Epo-TAg mice
and the mutant strain Nan [28], which bears a Bgl II
polymorphism at the 3' end of the endogenous Epo gene,
Epo-TAg and the endogenous Epo gene were shown to be
allelic (Fig. 2B).
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Table 2. Hematocrits of transgenic mice from each line and from non-
transgenic control mice
Line Construct Hematocrit
non-transgenic 43.0 5.1 (197)
37.6 LC Epo-M, 5' del 43.0 4.6 (13)
35.6
37.6 HC
198.3
Epo-M
Epo-M
Epo-M
46.1 1.9 (10)
46.1 4.9 (11)
68.8 6.6 (28)
134.3 HC
175.5
176.5
188.1 LC
188.1 HC
188.3
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
43.6 2.1 (7)
48.8 5.0 (23)
54.1 6.1 (l8)
40.4 7.8 (18)
47.3 7.0 (55)
44.7 3.8 (9)
134.3 LC, heterozygotes
134.3 LC, homozygotes
TAg-homo
TAg-homo
34.4 3.5 (7Q)
13.2 3.3 (l8)
Values are given as mean SD, and the number of observations is
shown in brackets.
a Significant difference from the non-transgenic group (Student's
t-test, P < 0.05)
Hematocrits from transgenic and non-transgenic animals of
the same stock are shown in Table 2. Among the Epo-M lines
only 198.3 was polycythemic. Of the Epo-TAg lines, 176.5,
175.5 and 188.1 HC were mildly polycythemic. Heterozygous
mice of the 134.3 LC line containing the homologously inserted
Epo-TAg transgene were significantly anemic when compared
to non-transgenic controls. Homozygous mice of the 134.3LC
line, in which both copies of the Epo gene are modified, were
severely anemic; however, they appeared in litters at the
predicted frequency, suggesting that fetal and neonatal viability
were normal.
Transgene expression was studied at the mRNA level using
RNAse protection assays. Male and female animals were stud-
ied both in the unstimulated state and after induction of acute
hemolytic anemia with phenylhydrazine. Ten organs were
studied: kidney, liver, brain, heart, lung, spleen in all animals;
preputial gland and testis in males, and ovary and uterus in
females. Expression in the acutely anemic animals is summa-
rized in Table 3.
Of the four lines containing the intact Epo-M transgene, one
(38.5) showed no expression in any organ. In the remaining
three, inducible expression was observed in both liver and
kidney. Although this pattern of dominant hepatic and renal
expression was similar to that of the endogenous Epo gene,
differences were observed. Expression of the transgene in the
liver of anemic mice was many-fold greater than that of the
endogenous gene. In contrast, transgene expression in the
kidney was lower than that of the endogenous gene, the relative
abundance of transgenic Epo mRNA being less than 30% of the
abundance of endogenous Epo mRNA in lines 35.6, 198.3 and
37.6 HC (Table 3, Fig. 3). Relative to induced expression in
kidney and liver, low levels of transgene and endogenous Epo
gene expression were detected by RNAse protection assays in
brain, ovary, testis and preputial gland. In general, the levels of
transgene mRNA were somewhat greater than that of endoge-
nous Epo mRNA in these organs. A high constitutive level of
aberrant expression was present in the uterus of two lines, 37.6
HC and 198.3. One further line (37.6 LC) contained a single
incomplete copy of Epo-M in which approximately 7.2 kb of 5'
sequence was missing. Highly inducible expression was ob-
served in liver at a level similar to that seen in the other lines,
but there was no expression in kidney.
Six out of seven lines bearing the Epo-TAg transgene at
heterologous insertion sites showed a tissue-specific pattern Of
transgene expression which was very similar to that of the
endogenous Epo gene; one line showed no expression. In
anemic animals from all six expressing lines expression was
predominantly renal. The level of Epo-TAg mRNA induced was
different in each line and varied from less than 3% (134.3 HC) to
approximately 30% (188.1 LC) of the abundance of endogenous
Epo mRNA (Table 3, Fig. 4). In kidneys of non-anemic animals
Epo-TAg mRNA was below the limit of detection. A difference
from the Epo-M lines was observed in hepatic expression.
Whereas Epo-M lines overexpressed the transgene in liver at
least tenfold, in five out of six Epo-TAg lines the ratio of hepatic
to renal transgene expression resembled the ratio of expression
for the endogenous gene (Figs. 3 and 4). In the 176.5 line a high
level of inducible transcription was observed in liver which was
aberrantly initiated. This was also seen, but to a lesser extent,
in liver in the 188.1 HC and 134.3 HC lines. In most other
organs Epo-TAg mRNA was below the limit of detection except
for the preputial gland of all six expressing lines, and low levels
in the testis (four lines), ovary (two lines) and uterus (two lines).
In the line bearing the Epo-TAg transgene at the homologous
insertion site (134.3 LC), the pattern of expression was essen-
tially identical to that of the endogenous Epo gene (Fig. 4).
While inducible renal expression was substantially higher than
in lines bearing the heterologously inserted transgenes, expres-
sion outside the liver and kidney was lower.
Immunohistoche,nical localization of Epo- TAg expression
Studies of the cellular distribution of renal expression of
Epo-TAg were performed on paraffin-embedded sections from
perfusion-fixed kidneys using a polyclonal rabbit antiserum
against SV4O T Ag. All animals studied were between one and
three months of age and were either unstimulated or stimulated
acutely with phenyihydrazine. No abnormalities were observed
in the renal tubules or glomeruli. The renal interstitium also
appeared normal, in particular the interstitial cell density was
similar between non-transgenic and transgenic mice (Table 4).
In anemic Epo-TAg mice, immunoreactive SV4O T Ag was
induced in a population of renal interstitial cells (Figs. 5 and 6).
Staining was confined to the nucleus (Fig. 7A). The same
pattern of expression was observed in mice with the homolo-
gously inserted Epo-TAg transgene (134.3 LC) and in mice
bearing heterologously inserted transgenes (188.1 LC, 188.3,
188.1 HC and 176.5). This pattern of expression was not only
observed in mice with anemia induced by phenylhydrazine, it
was also seen in iron deficiency anemia, the congenitally
anemic 134.3 LC homozygotes and crosses with Nan mice
which have a hemolytic anemia (data not shown). No staining
was seen in kidneys from non-transgenic mice.
All cells expressing SV4O T Ag were within the renal inter-
stitium. No glomerular or tubular staining was observed in any
animal. In kidneys from unstimulated animals a few cells were
positive for 5V40 T Ag, and these were located in the deep
cortex. In kidneys from anemic animals an increased number of
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Table 3. Transgene expression in mice rendered acutely anemic with phenyihydrazine
Line Construct
Copy
no. Kidney Liver Brain Heart Lung Spleen
Preputial
gland Testis Ovary Uterus
37.6 LC Epo-M, 5' del I — +(26%) + — — — — — + +
38.5
35.6
37.6 HC
198.3
Epo-M
Epo-M
Epo-M
Epo-M
I
1
16
64
-
+(<3%)
+(22%)
+(27%)
-
+(35%)
+(43%)
+(l44%)
—
+
+
+
—
—
—
—
-
—
—
—
—
—
—
—
—
—
+
+
—
—
+
+
NE
—
+
+
NE
+
+
+
99.5
134.3 HC
175.5
176.5
188.1 LC
188.1 HC
188.3
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
Epo-TAg
I
23
13
21
2
19
2
-
+(<3%)
+(4%)
+(<3%)
+(27%)
+(4%)
+(21%)
—
+(<3%)
—
—
+(<3%)
—
+(<3%)
-
—
+
+
—
—
—
-
—
—
—
—
—
—
-
—
—
—
—
—
—
—
—
—
—
—
—
—
NE
+
+
+
NE
+
+
NE
+
+
+
NE
+
+
—
—
—
+
+
—
—
-
—
—
—
+
+
NE
134.3 LC Tag-homo 1 +(l0O%) +(<3%) + — — — + + —
The level of correctly initiated expression was assayed by RNAse protection. For most organs 150 g was assayed, but for heart, lung and ovary
the amount of RNA was less and 50 g was assayed. The riboprobe enabled separate detection of transgenic and endogenous Epo mRNA in each
sample (Figs. 3 and 4). Transgene expression in kidney and liver was quantitated by scintillation counting and related to the renal expression of
endogenous Epo mRNA in that animal (corrected appropriately for the difference in the length and nucleic acid content of the protected fragment),
and is indicated in brackets as a percentage. Transgene expression in other organs is indicated as + (detectable) or — (not detectable), NE = not
examined. Using this assay, endogenous Epo gene expression was detectable at a low level in the brain, preputial gland, testis and (in some cases)
in the ovary of anemic mice, but not in heart, lung, spleen or uterus.
cells were positive in the deep cortex, but with more severe
stimulation recruitment was observed, with cells expressing
SV4O T Ag being observed throughout the cortex and outer
stripe of the outer medulla (Figs. 5 and 6). Some cells between
thick ascending limbs of Henle's loops in the outer portion of
the inner stripe of the outer medulla also expressed SV4O T Ag.
The cell density throughout the cortex was not uniform and the
cells often appeared in small clusters. In sections from severely
anemic mice, approximately 40% of all interstitial cells stained
positively in the deep cortical regions (Fig. 6). The cells
themselves had nuclei of variable shape, and using conventional
counterstaining the cytoplasm was rather poorly visualized.
Further characterization of the cells expressing SV4O T Ag
was performed using antibodies to cytoplasmic antigens in
double immunohistochemical labeling studies. First, colocaliza-
tion of SV4O T Ag with endothelial markers was studied. Rabbit
antiserum to human Factor Vill-related antigen did not cob-
calize with the antibody to SV4O T Ag. Although intense
staining of the endothelium of large vessels was observed,
capillary staining with this antiserum was much less intense
leaving some doubt as to the security of this negative result.
Therefore, further studies were performed with a rat anti-mouse
PECAMJCD31 mAb. This antibody reacted strongly with cap-
illary endothelium in the interstitium. Endothelial nuclei were
clearly demonstrated and all were negative for SV4O T Ag (Fig.
7B). Likewise, no cell expressing SV4O T Ag expressed
PECAM/CD31, indicating that these cells were not endothelial.
The non-endothelial cell populations within the renal intersti-
tium include several leukocyte populations: macrophages, lym-
phocytes and a cell population of dendritic form which is of
bone marrow origin [29]. All of these cells bear leukocyte
common antigen (CD45). A rat anti-mouse CD45 mAb was used
to determine whether there was SV4O T Ag in CD45 bearing
cells. Although a substantial interstitial population was CD45
positive, none of the SV4O T Ag expressing cells stained with
this mAb (Fig. 7C). Sections were also stained with rabbit
polyclonal antiserum to the macrophage F4/80 antigen. Inter-
stitial cells expressing F4/80 antigen were observed in both
cortex and medulla, but, as is consistent with the studies of
CD45 expression, these cells were distinct from those express-
ing SV4O T Ag. Interestingly, a significant proportion of SV4O T
Ag-expressing cells, in the region of 5%, appeared to be closely
apposed to cells expressing CD45 and F4/80 antigen. Double
staining was also performed for SV4O T Ag with mAbs to Class
II MHC and to Thy 1. Rather fewer interstitial cells expressed
Class II MHC or Thy 1 than had been identified with the CD45
mAb, and none of these cells was positive for SV4O T Ag.
The renal interstitium also contains cells which have been
classified as fibroblast-like on morphological grounds [16].
Recent studies have characterized the expression of the ectoen-
zyme 5' NT in the renal interstitium using histochemical and
immunohistochemical techniques [22, 30]. These studies indi-
cate that this antigen is expressed by these resident cells and by
lymphatic endothelium, but not by capillary endothelium. Us-
ing a rabbit antiserum against 5' NT a high proportion of the
SV4O T Ag expressing cells were doubly stained. However, not
all SV4O T Ag expressing cells expressed 5' NT and many 5' NT
staining cells did not express SV4O T Ag.
Interstitial staining with 5' NT was essentially confined to the
cortex and was most intense in the deep cortex, where SV4O T
Ag positive cells were also most frequent. However, in severely
anemic animals, although substantial numbers of cells positive
for SV4O T Ag were observed between proximal tubules in the
outer medulla, interstitial staining with 5' NT was weak or
absent in this region. In addition to this regional difference in
antigen expression, within a particular high power field it was
often possible to discern cells which were apparently only
expressing SV4O T Ag, or only 5' NT, adjacent to cells which
were doubly positive (Fig. 7D). Double staining was also
observed with the fibroblast marker ER-TR7. In contrast with
5' NT, this was seen both in the cortex and outer medulla, but,
as with 5' NT, overlap was not complete with some cells
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many in the inner stripe of the outer medulla were negative. In
all positively stained cells, the gold particles were specifically
located over the electron-lucent euchromatin, with few parti-
cles over the electron-dense heterochromatin (Figs. 8B and 9B).
The specificity of the staining was confirmed by the absence of
staining in the same cells in serial sections stained with rabbit
anti-toxoplasma antiserum or normal rabbit serum.
In sections stained for 5' NT, labeling was observed in
mesangial cells of the glomerulus and in the apical cytoplasm,
but not the microvilli, of proximal tubular cells. In addition, the
fibroblast-like cells in the interstitium showed positive staining
with the gold particles predominantly located along the plasma
membrane and outlining the numerous fine cytoplasmic pro-
cesses formed by these cells (Fig. 9C). Capillary endothelial
cells were negative. When serial sections stained for SV4O T Ag
and 5' NT were examined, it was possible to confirm that
individual cells positive for SV4O T Ag were also positive for 5'
NT (Fig. 9 B and C).
Discussion
TG TG Non-TG
Fig. 3. RNAse protection assay showing inducible expression in the
kidney (K) and liver (L) of37.6 HC (TG) and non-transgenic (non-TG)
mice. The first two lanes show RNA from an unstimulated 37.6 HC
mouse; no transcripts are seen. The next two lanes show RNA from an
acutely anemic 37.6 HC mouse; one band is seen from the transgene
(221 bp) and two bands (148 bp and 65 bp) are seen to arise from the
endogenous gene in kidney (Fig. 1A). In liver, the transgene is overex-
pressed and there are additional aberrantly initiated transcripts. In the
right hand two lanes, RNA from an acutely stimulated non-transgenic
mouse is shown for comparison.
expressing only SV4O T Ag or ER-TR7 lying close to doubly
positive cells.
Immunoelectron microscopy
Ultrastructural examination of the mid and deep cortex
showed nephron segments, capillaries and small areas of inter-
stitial tissue between the tubules. These features were similar to
those previously described in the rat [16]. Although sub-
optimally fixed because of the omission of post-fixation with
osmium tetroxide, non-endothelial interstitial cells appeared to
be predominantly fibroblast-like with a few rounded mononu-
clear cells (Fig. 8A). The fibroblast-like cells were pleomorphic
in shape, presenting flattened or stellate profiles with intercon-
necting cytoplasmic processes between neighboring cells (Figs.
8A and 9A). In sections stained for SV4O T Ag, examination of
the epithelial, endothelial and interstitial cells showed that
staining was limited to the nuclei of the interstitial fibroblast-
like cells (Fig. 8B). However, not all fibroblast-like cells were
positive. While the majority of these cells in the cortex of
animals with a hematocrit below 20% was positively stained,
The production of Epo-TAg mice provided a novel means for
identification of the Epo-producing cells in the kidney. In
addition, comparison of the three types of transgenic mice gives
new information regarding the organization of cis-acting se-
quences required for tissue-specific expression of the gene.
When mice bearing the mutated Epo (Epo-M) and the Epo-
SV4O T Ag fusion gene (Epo-TAg) are considered together, nine
out of eleven lines bearing the complete transgene showed
expression of the transgene in kidney which was inducible by
anemia. This indicates that cis-acting sequences which regulate
renal Epo are within the transgene boundaries, 9 kb 5' and 3.5
kb 3' to the mouse Epo gene.
In studies of expression of the human Epo gene in transgenic
mice, Semenza and colleagues have compared the expression of
human Epo transgenes containing 0.7 kb of 3' sequence and 0.4
kb, 6.0 kb and 14 kb of 5' sequence. The 0.4 kb transgene was
widely expressed but inducible only in liver [31]. The 6.0 kb
transgene was also inducibly expressed in liver but was less
widely expressed and, in particular, not expressed in kidney
[32], and the 14 kb transgene was inducibly expressed in kidney
as well as liver [33]. One important conclusion from this work is
that the cis-acting sequences involved in hepatic and renal
expression are different and that expression of Epo in the
kidney is dependent on sequences between 6 and 14 kb 5' to the
human gene. Our 37.6 LC line, which bears a single truncated
copy of Epo-M with only 1.8 kb of 5' sequence, expressed in
liver but not kidney. This is consistent with a similar organiza-
tion for the mouse gene, with sequences important for renal
expression lying between 1.8 kb and 9 kb 5' to the gene.
Although inducible expression in liver and kidney was ob-
served in Epo-M lines, the ratio of hepatic to renal expression
was much greater than normal. This result indicates that
repression of hepatic Epo expression in adult animals is depen-
dent on sequence not contained in the transgene, and is thus
distinct from the sequence necessary for renal Epo expression.
In contrast with the Epo-M lines, hepatic overexpression was
not seen in Epo-TAg lines (with the exception of 176.5, where
the transcripts were unusual in being aberrantly initiated). A
possible explanation for this difference in hepatic expression is
that the insertion distances the Epo promoter from the 3'
Epo-T Ag
Epo
Fig. 4. RNAse protection assay showing expression of the Epo-TAg trans gene in seven different organs from acutely anemic mice of three
different lines. The Epo-TAg mRNA produces a band of 120 bp and the endogenous Epo mRNA a band of 65 bp. Kidney RNA from an acutely
stimulated non-transgenic mouse is shown in the right hand lane for comparison. No transgene or endogenous gene expression is seen in any organ
other than kidney or liver in this assay. The level of Epo-TAg and endogenous gene expression is much higher in kidney than in liver.
enhancer, which is known to operate powerfully in transfected
hepatoma cells [34—36]. Reduction in hepatic, but not renal,
expression in these lines is further evidence that the cis-acting
mechanisms controlling expression of the gene in liver and
kidney are different.
Although the major sites of Epo gene expression are the liver
and kidney, we have previously demonstrated that the gene is
also expressed at a low level in the rat brain and testis [19, 371.
In the present study, this was also found to be true of the
endogenous Epo gene in the mouse. Additionally, we observed
a low level of endogenous Epo gene expression in the preputial
gland of anemic male mice and in the ovary in some, but not all,
anemic female mice. In most of the transgenic lines bearing
either Epo-M or Epo-TAg, slight overexpression of the trans-
gene was observed at one or more of these sites.
In the 134.3 LC line restriction mapping indicated that the
Epo-TAg construct had replaced one copy of the endogenous
gene. The founder animal 134.3 gave rise to two types of
offspring, one bearing the homologous insertion (134.3 LC) and
a second bearing a high copy Epo-TAg insertion (134.3 HC).
The high copy insertion was separately inherited in a pattern
which was unlinked to the endogenous Epo gene and therefore
was clearly at a heterologous site. Using an Eagi/SalI restric-
tion digest we were able to demonstrate that the homologous
insertion was present in DNA from the tail of the founder
animal (data not shown). This founder animal 134.3 must have
been a germ line mosaic for transgenic and non-transgenic cells,
since transgenic offspring were rare (1 in 54), its litter size was
good (average 10), and there was no obvious embryonic lethal-
ity in any of the derived transgenic lines. Insertion of the
transgene at the two independently segregating sites must
Table 4. Comparison of the number of interstitial cells in two
transgenic mice and two non-transgenic littermates
Cortex Outer
stripeOuter Middle Inner
Transgenic 1296 170 1397 139 1430 373 1712 341
Controls 1296 106 1362 90 1408 182 1752 157
The number of interstitial nuclei in each of three 250 .cm strips was
assessed in sections stained with PAS. The number of nuclei per mm2
in each region is shown (mean SD of six values, three from each
animal).
therefore have occurred late in the S-phase of the first cell
cycle, or some time thereafter.
We are aware of only one previous report of homologous
"targeted" insertion following pronuclear injection of mouse
eggs. In that report, correction of a deletion in the mouse MHC
class II En gene was achieved using a 2.56 kb genomic fragment
from the Eit locus [381. A total of 506 transgenic pups was
screened for homologous insertion and one was identified. As
the authors pointed out, that experiment was not optimized for
homologous recombination because the region is highly poly-
morphic and an En" allele was used in the attempts to correct
deletions in either Eas or En" alleles. In the Epo-TAg construct
SV4O sequence was flanked on each side by approximately 8 kb
of mouse sequence, in a manner resembling a gene replacement
vector [39]. The transgenic DNA was cloned from a BALB/c
genomic library and is therefore not isogenic. However, Epo is
a highly conserved gene and a much higher level of homology
might be anticipated than at the MHC Class II locus. Clearly,
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Fig. 5. A. Section of a kidney from an acutely
anemic 134.3 LC Epo-TAg mouse (hematocrit
17%), showing the distribution of SV4O T Ag
positive nuclei. The transverse section shows
the full thickness of the cortex and the outer
stripe of the outer medulla, and a part of the
inner stripe of the outer medulla. Glomeruli
(G) are identifiable in the cortex. Nuclei
positive for T Ag are seen as black dots lying
between the tubules, and are visible through
the entire depth of the cortex and in the outer
stripe of the outer medulla. Magnification
x50. B. Control section from the same area of
the kidney shown in A. The antiserum to
SV4O T Ag was replaced with normal rabbit
serum. The level of background staining is
low, and the interstitial nuclear staining seen
in A is specific for T Ag. Magnification x50.
from our observation of one homologous insertion among
thirteen transgenic lines we cannot determine the frequency of
this type of event. However, given the increased rate of
homologous recombination in embryonic stem cells obtained by
using isogenic DNA and long arms of homologous sequence
[40, 41], the rate following injection with a favorable construct
may be much higher than that reported by Brinster and Palmiter
[38].
The pattern of expression of the homologously inserted
Epo-TAg gene was the same as that of the endogenous Epo
gene. Aberrant expression was not observed. Inducible expres-
sion in kidney was greater than that of heterologously inserted
Epo-TAg transgenes. This result provides further evidence that
sequence outside the 16.5 kb included in the transgene is
involved in the regulation of Epo gene expression. The renal
cellular localization of SV4O T Ag in the 134.3 LC mice, in
which the marker gene was in the context of all cis-acting
sequence, was identical to that observed in the other Epo-TAg
animals. This adds further evidence that SV4O T Ag is serving
as a faithful marker of Epo expression in the kidney.
Numerous attempts have been made to identify Epo-produc-
ing cells within the kidney [reviewed in 2]. In situ hybridization
studies have localized Epo mRNA within the non-glomerular
portion of the renal cortex. One study reported a renal tubular
localization of Epo mRNA but used 32P labeled probes which
may have impaired resolution [42]. Other studies have consis-
tently indicated an interstitial localization for renal Epo mRNA
[7, 9—12]. However, further cellular characterization has been
difficult because of the absence of distinctive morphology under
light microscopy, difficulty in combining in situ hybridization
with immunohistochemjcal and ultrastructural studies, and lim-
ited availability of specific antisera to renal interstitial cell
markers.
In our transgenic mice, the pattern of interstitial cell staining
for SV4O T Ag was identical in a number of distinctive ways to
that described for in situ hybridization of Epo mRNA. Firstly,
Hematocrit
Fig. 6. Histogram showing distribution of Epo-producing cells in the
mouse kidney and recruitment in anemia. Data from four transgenic
mice (134.3 LC heterozygotes) are shown; three of the mice were
rendered anemic to different degrees with phenylhydrazine. The kid-
neys were perfusion fixed and paraffin embedded. In each mouse three
strips of width 250 m running perpendicular to the capsule were
assessed, which traversed the full thickness of the cortex and outer
stripe of the outer medulla. The cortex was subdivided into thirds on the
basis of depth. The percentage of interstitial nuclei positive for SV4O T
Ag is shown (mean of three values). Error bars show SD. In the
unstimulated mouse (hematocrit 47%) there were too few positive cells
for this method to be representative, In this kidney all the positive cells
in a transverse section of the kidney were counted, and the total number
of interstitial cells was estimated from the data in Table 4. Symbols are:
(U) outercortex; () mid cortex; (D) inner cortex; () outer stripe.
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Fig. 7. A. Kidney sect ion from a stimulated 134.3 LC heterozygote immunostained for SV4O TAg and counterstained with PAS, showing a region
of deep cortex. Four glomeruli (G) are seen. Positive nuclei (brown) lie between the tubules. Magnification X 125. 8. Double staining for SV4O I
Ag and PECAM/CD3 1. Four nuclei positive for SV4O T Ag (black) are seen to lie between four tubules. The endothelium of four capillaries is
positive for PECAM/CD31 (pink). An endothelial nucleus is seen (En) which is not positive for SV4O T Ag. Magnification x 900. C. Double staining
for SV4O T Ag and CD45. Several nuclei positive for SV4O T Ag are seen (black), and two CD45 positive cells are shown (pink), which are negative
for 5V40 T Ag. Magnification x 900, D. Double staining for SV4O I Ag and 5' NT. Twointerstitial cells positive for 5' NT are seen (red staining)
lying adjacent to a proximal tubule. One of these is also positive for SV4O T Ag (black nucleus). Several other interstitial cells are negative for both
markers. There is some weak 5' NT staining of the brush border of the tubular cells. Magnification x 900.
as was described by Koury et al, the cells had large pleomor-
phic nuclei with little visible cytoplasm under light microscopy
using conventional counterstains [10, 11]. Secondly, the nuclear
expression of SV4O T Ag was highly inducible by anemia, and
with increasingly severe anemia many more cells expressed
SV4O T Ag. Thirdly, as with the in situ studies of Epo mRNA
[11], in moderately anemic animals positive cells were most
frequent in the deep cortex, but with more severe anemia
recruitment was observed throughout the cortex and in the
outer medulla. Koury and colleagues estimated that with severe
anemia up to 30% of interstitial cells in the deep cortex
contained Epo mRNA. This proportion is very similar to the
number of cells staining for SV4O T Ag in our severely anemic
mice. We did not perform in situ hybridization to directly
demonstrate that Epo mRNA and 5V40 T Ag were present in
the same cells for two reasons. First, it is difficult to preserve
antigenic epitopes under the conditons required for in situ
techniques. Secondly, the Epo-TAg transgene gave rise to
transcripts which would have been indistinguishable by in situ
hybridization from those arising from the endogenous Epo
gene.
Since we have not yet established these cells clonally in
tissue culture, we have not formally proved that they produce
Epo. Nevertheless, the distinctive features of Epo-TAg expres-
sion described above demonstrate that it is expressed in the
appropriate cells in the kidney. These transgenic mice thus
provided a new opportunity for characterization and isolation of
the Epo-producing cells. Nuclear staining for SV4O T Ag was
readily combined with staining for cytoplasmic antigens in
double immunohistochemical labeling studies and could also be
detected by immunoelectron microscopy, allowing ultrastruc-
tural studies. Results from both techniques were in agreement.
Interstitial cells staining with SV4O T Ag did not bear endothe-
hal or leukocyte markers. They were distinguished easily by
electron microscopy from interstitial macrophage and endothe-
hal cells and corresponded to the cortical fibroblast-like cells,
which have been classified as Type I interstitial cells in ultra-
structural studies of kidneys from rats [161. Since cells express-
ing SV4O T Ag did not express CD45, or Class II MHC, they are
distinct from the dendritic cells of bone marrow origin.
Resident cortical fibroblast-like cells in rodent kidneys have
not been well characterized with respect to specific antigenic
markers. However, renal expression of the ectoenzyme 5' NT
has been studied in detail by immunohistochemistry and histo-
chemistry [22, 30]. The enzyme is expressed strongly in the
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Fig. 8. Immunoelectron microscopy for SV4O T Ag. A. Low power electron micrograph from the deep cortex showing a group of interstitial
fibroblast-like cells (F) and a round monocyte-like cell (R) surrounded by proximal tubules (P) and capillaries (Ca). Bar is 5 m. B. Enlargement
of the enclosed area in A showing numerous gold particles over the euchromatin of the nucleus (arrowheads) of the fibroblast-like cells (F). Note
the absence of label over the endothelial cell (En) nucleus. Immunostained for SV4O T Ag. Bar is 0.5 m,
cortical interstitium as well as in proximal tubules, the interca-
lated cells of the distal tubule and collecting duct, and the
mesangium. Although it is clear that a large number of cell types
both within the kidney and elsewhere can express 5' NT, Le Hir
and Kaissling [30] have reported that this antigen is cell-type
specific in the renal interstitium. We examined co-expression of
SV4O T Ag and 5' NT using double-labeling of frozen sections
for light microscopy and labeling of sequential sections for
electron microscopy. SV4O T Ag staining nuclei were fre-
quently observed to be surrounded by a meshwork of 5' NT
staining cytoplasm by light microscopy. A similar result was
obtained using the fibroblast marker ER-TR7. Co-expression of
nuclear SV4O T Ag and 5' NT on the cytoplasmic membrane of
the same cell was confirmed by electron microscopy. In inde-
pendent work using the same antiserum Bachmann, Le Hir and
Eckardt have recently demonstrated localization of 5' NT on
the majority of the cells containing Epo mRNA in anemic rat
kidney [13].
We therefore conclude that the Epo-producing cells are the
fibroblast-like cells, based on surface marker expression and
ultrastructural characteristics. Furthermore, immunoelectron
microscopy demonstrated that the cells expressing SV4O T Ag
were all of fibroblast-like morphology, irrespective of whether
they were in the cortex (where co-expression of 5' NT was
common), or in the outer stripe of the outer medulla (where 5'
NT was not expressed in the interstitium). This fibroblast-like
population shows evidence of heterogeneity, both in terms of
Epo production and surface molecule expression. It is interest-
ing that 5' NT expression in this population is induced by
anemia. As is the case with erythropoietin, 5' NT expression
extends outwards from the deep to superficial cortex with more
severe anemia [43]. The apparent overlap between 5' NT and
Epo expression will therefore vary with the severity and timing
of stimulation as well as with the sensitivity of the detection
method. However, the absence of complete overlap indicates
that it is unlikely that induction of 5' NT expression is neces-
sary for Epo expression or vice-versa.
Growth of fibroblast-like cells occurs in primary cultures of
kidney cells and many established renal cell lines are classified
as fibroblastoid, yet these cell cultures do not produce Epo [2].
It is also notable that fibroblast proliferation is common in many
forms of renal disease but that Epo deficiency is the rule. One
possible explanation for this paradox is that co-operative cell
interactions are required for Epo production in kidney, which
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Fig. 9. immunoelectron microscopy for 5V40 T Ag and 5' NT. A. Low power electron micrograph of three fibroblast-like cells (F) between
proximal tubules (P) and capillaries (Ca). Bar is 2 sm. B. Detail of the enclosed area in A immunostained for SV4O T Ag, showing localization of
gold over the nuclear euchromatin (arrowheads). Bar is 0.5 sm. C. Serial section of the same fibroblast-like cell as in B immunostained for 5' NT,
showing localization of gold along the plasma membrane (arrowheads). Bar is 0.5 sm.
are destroyed in renal disease and are not met in tissue culture.
Equally, it is possible that the proliferating fibroblastoid cells
may not be equivalent to the fibroblast-like cells in the normal
kidney or that proliferation itself may reduce the facility for Epo
gene expression.
Anemia was observed in the heterozygous 134.3 LC mice in
which one copy of the endogenous Epo gene had been replaced
by the Epo-TAg fusion gene. Thus, it appears that expression of
the remaining copy of the endogenous Epo gene cannot be
appropriately increased in compensation. The Epo-TAg con-
struct contained the poly A addition signals 3' to the SV4O T Ag
coding sequence. Nevertheless, RNAse protection indicated
unexpected, but significant, transcription of Epo sequence 3' to
this region. Mapping of these transcripts indicated that they
were contiguous with the SV4O T Ag insertion and almost
certainly arose from continued transcription rather than from a
second cryptic promoter. This part of the Epo-TAg gene
contained the entire Epo coding sequence (Fig. 1). It is there-
fore likely that some of these transcripts were functional,
accounting for the viability of homozygous 134.3 LC mice in
which both copies of the Epo gene were replaced by Epo-TAg.
Consistent with this, these mice have reduced, but detectable,
Epo on immunoassay (data not shown).
We observed polycythemia in some transgenic lines. Among
animals bearing Epo-M, polycythemia was only seen in the
198.3 line. It is not clear whether polycythemia arose from a
minor dysregulation of renal or hepatic expression, or whether
unregulated expression from other sites was responsible. A
similar phenomenon was reported recently by Semenza and
colleagues in mice bearing human Epo transgenes [31, 33].
Since the Epo-TAg fusion gene can produce functional Epo,
similar mechanisms could explain polycythemia in some of the
Epo-TAg animals. Alternatively, increased transcription of the
endogenous Epo gene in renal or extrarenal cell populations
expanded as a consequence of SV4O T Ag expression might
account for the polycythemia. However, polycthemia did not
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correlate with the level of renal Epo-TAg expression in the
different lines, nor have we seen any clear evidence of expan-
sion of the Epo-expressing renal cell population in polycythe-
mic animals.
Although tissue specific expression of SV4O T Ag has enabled
identification of the Epo-producing cell population in kidney,
the further goal of inducing tumor formation and transformed
cell lines has not yet been achieved. To date we have not
observed renal tumor formation in 89 Epo-TAg mice from the
seven expressing lines observed for periods of greater than six
months. Moreover, there did not appear to be any expansion of
the interstitial cell population in the kidneys examined histolog-
ically. In contrast, in the six lines in which Epo-TAg was
inserted at heterologous sites in the genome and expressed at a
moderate level in the preputial gland, all males showed marked
hyperplasia of that gland, indicating that the SV4O T Ag
produced by the transgene was functionally intact. It is possible
that failure to induce proliferation of the renal interstitial cells
simply reflects the tight regulation of the Epo-TAg transgene in
kidney, with consequent low expression of SV4O T Ag in mice
with normal hematocrits. Equally, it is recognized that some
cell populations are resistant to the proliferative action of SV4O
T Ag [44, 45]. Studies of the behavior of hypoxically cultured
explanted tissue and of animals made chronically anemic are in
progress and should provide further information on the biology
of these cells.
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